- Head-to-head data presentations will show PRECISION1 superior
over competitive lenses on critical success factors for new contact
lens wearers
- Clinical findings on AcrySof IQ PanOptix trifocal intraocular
lens for the treatment of cataracts to be presented for the
first-time ever at a major optometry meeting
- Robust onsite program will give meeting goers hands-on
experiences with PRECISION1 contact lenses, the iLUX MGD Treatment
System and more
Alcon, the global leader in eye care and official sponsor of
20/20™, will bring major contact lens and cataract innovations
together for the first time at the 2019 American Academy of
Optometry (AAO / #Academy19) meeting taking place October 23-27 at
the Orange County Convention Center (OCCC) in Orlando, Fla.
Innovations like the newly launched PRECISION1® daily disposable
contact lenses, AcrySof® IQ PanOptix® Trifocal Intraocular Lens
(IOL), and the iLUX® MGD Treatment System will be included in
nearly 20 lectures, podium and poster presentations during Alcon’s
first major optometry meeting since becoming an independent
company. This year’s robust clinical and educational program
reinforces Alcon’s commitment to providing life-changing vision and
eye care products that help people see brilliantly.
“This is an exciting time for Alcon – the speed and volume at
which we are introducing innovations for a range of eye conditions,
life stages and lifestyles are unprecedented,” said Sean Clark,
General Manager, U.S. Vision Care, Alcon. “We are especially
energized to connect with the optometry community following the
recent launches of PRECISION1 and PanOptix to outline our plans for
the future, showcase the breadth of our portfolio, and share new
data, along with practice insights and educational resources that
deliver on our promise to help people see brilliantly.”
PRECISION1 Contact Lenses Set to Debut at #Academy19
In August, Alcon launched PRECISION1 in the U.S. as the first
mainstream daily disposable contact lens to use proprietary
SMARTSURFACE® technology to deliver precise vision and long-lasting
comfort. This new contact lens innovation will make its debut at
this year’s AAO meeting. Data presented at the meeting will
demonstrate the superiority of PRECISION1 against the leading daily
disposable contact lens on key clinical endpoints – vision, comfort
and handling. Conference attendees will also have the opportunity
to try on the new lenses at the Alcon booth. Meeting activities
around PRECISION1 include:
- Wednesday, October 23 – Friday, October 25
- Lens Try-on: Stop by and experience first-hand why PRECISION1
is the lens for new wearers to start in and stay in at Alcon booth
#916 during exhibit hall hours (OCCC, Exhibit Hall)
- Thursday, October 24
- Contact Lens Super Session: Low Friction and Low Modulus
Contact Lens Surfaces Improve Lubricity and Reduce Cell Damage in
Corneal Epithelial Cell Models, Presented by Dr. W. Gregory Sawyer
(1:45 – 2:00 p.m., Room W224 ABC)
- Exclusive Launch Event: Introducing Alcon’s Newest Contact Lens
Innovation, Presented by Drs. Katie Spear and Rick Weisbarth (7:00
p.m., Hyatt Regency Orlando). Space is limited. To register, visit
https://cvent.me/ZQELM3
- Friday, October 25
- Poster Presentation (#048): Clinical Performance of a New
Silicone Hydrogel Daily Disposable and a HEMA-Based Daily
Disposable Contact Lens, Presented by Dr. Stacie Cummings (10:00
a.m. – 12:00 p.m., West Hall D1)
- Poster Presentation (#058): Clinical Lens Fit Characteristics
Assessments of a New Silicone Hydrogel Daily Disposable and Two
Commercially Available Daily Disposable Contact Lenses, Presented
by Dr. Katie Spear (10:00 a.m. – 12:00 p.m., West Hall D1)
- Poster Presentation (#062): Characterization of the Surface
Properties of a Novel Daily Disposable, Silicone Hydrogel Contact
Lens, Presented by Dr. Robert Tucker (10:00 a.m. – 12:00 p.m., West
Hall D1)
- Poster Presentation (#065): Clinical Performance of a New Daily
Disposable Spherical Contact Lens, Presented by Dr. Stacie Cummings
(1:00 – 3:00 p.m., West Hall D1)
PanOptix Trifocal IOL to Make First-Ever Appearance at
Optometry Meeting
Alcon will also feature data on the recently launched AcrySof IQ
PanOptix, the first-and-only FDA-approved advanced trifocal IOL in
the U.S. The inclusion of clinical study findings on PanOptix at
AAO demonstrates Alcon’s commitment to educating eye care
professionals on the latest cataract treatment options that deliver
optimal patient outcomes.
The innovation will be featured in poster presentations where
the PanOptix IOL is clinically shown to deliver an exceptional
combination of near, intermediate and distance vision while
significantly reducing the need for glasses after surgery.1,2
Optometrists and staff interested in learning more about this new
presbyopia-correcting option for their cataract patients can stop
by the PanOptix section of the Alcon booth #916 for more
information. Clinical presentations include:
- Friday, October 25
- Poster Presentation (#108): Visual Performance of a Novel
Trifocal IOL, Presented by Dr. Walter Whitley (10:00 a.m. – 12:00
p.m., West Hall D1)
- Poster Presentation (#110): Depth of Focus Evaluation of a
Trifocal IOL, Presented by Dr. Justin Schweizer (10:00 a.m. – 12:00
p.m., West Hall D1)
Building on Alcon’s Clinical Legacy in Dry Eye
Management
Clinical and educational activities will take place at AAO
around Alcon’s robust portfolio of dry eye devices and solutions.
Specifically, the iLUX MGD Treatment device and SYSTANE® Complete
lubricant drops will be featured in poster sessions that add to
existing clinical data that show efficacy in personalized therapy
for dry eye symptom relief. Meeting attendees will also have the
opportunity to receive a hands-on experience with the iLUX device
and learn more about Alcon’s practice implementation program, DEEP™
(Dry Eye Excellence Program), at the Alcon booth. There will also
be 1:1 demonstrations taking place in Alcon’s private suite – stop
by the Alcon booth to learn more. Dry eye presentations
include:
- Thursday, October 24
- Lecture: Effectiveness of In-Office Heating and Expression
Devices for the Treatment of Meibomian Gland Dysfunction, Presented
by Dr. Mohinder Merchea (8:30 – 8:45 a.m., Tangerine WF2)
- Poster Presentation (#043): Sustained Symptom Relief Following
a Single Dose of PG/HPG-Nanoemulsion in Patients with Dry Eye
Disease, Presented by Dr. Michael Guillon (4:30 – 6:30 p.m., West
Hall D1)
- Poster Presentation (#053): Tear Lipid Layer Thickness Changes
with Use of Emollient Eye Drops, Presented by Dr. Kimberly
Wiesenberger (4:30 – 6:30 p.m., West Hall D1)
- Friday, October 25
- Anterior Segment Section Symposium: Rosacea, Ocular Rosacea,
and MGD: A Review and New Treatments, Moderated by Dr. Scott Han
(2:00 – 4:00 p.m., Tangerine WF1)
- Poster Presentation (#098): Investigation of Systane Complete
to Relieve Contact Lens Related Dry Eye and Discomfort, Presented
by Dr. Chris Lievens (10:00 a.m. – 12:00 p.m., West Hall D1)
- Poster Presentation (#092): Changes in Symptoms of Dry Eye with
Regular Use of Artificial Tear Containing Nano-Droplet Emollient,
Presented by Dr. Jennifer Fogt (10:00 a.m. – 12:00 p.m., West Hall
D1)
Visit the Alcon booth #916 for important information on Alcon’s
innovative products and programs featured in this release.
Important Information About PanOptix
The AcrySof® IQ PanOptix® Trifocal IOL is a type of multifocal
IOL used to focus images clearly onto the back of your eye (retina)
to allow clear vision after the cataract removal. In addition, the
center of the AcrySof® IQ PanOptix® Trifocal IOL allows for better
near (reading) vision and intermediate (computer work) vision
versus what a monofocal lens would provide.
Potential Side Effects: Due to the design of multifocal IOLs,
there are some side effects that can be associated with the
AcrySof® IQ PanOptix® Trifocal IOL models. These may be worse than
with a monofocal IOL, including visual disturbances such as glare,
rings around lights, starbursts (rays around light sources), and
reduced contrast sensitivity (decrease in ability to distinguish
objects from their background, especially in dim lighting). These
side effects may make it more difficult to see while driving at
night or completing tasks in low lighting conditions such as at
night or in fog, or in a dimly lit room after surgery as compared
to before surgery.
Further, a toric IOL corrects astigmatism only when it is placed
in the correct position in the eye. There is a possibility that the
toric IOL could be placed incorrectly or could move within the eye.
If the toric lens is not positioned correctly following surgery,
the change in your astigmatism correction by the IOL, along with
any necessary correction with glasses, may cause visual
distortions. If the lens rotates in your eye, you may need
additional surgery to reposition or replace the IOL.
Important Information on the iLUX® Device
The iLUX® Device is indicated for the application of localized
heat and pressure therapy in adult patients with chronic disease of
the eyelids, including Meibomian Gland Dysfunction (MGD), also
known as evaporative dry eye. Please refer to the User Manual for a
complete list of contraindications, instructions for use, warnings
and precautions of the iLUX® Device.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “anticipate,”
“intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,”
“seek,” “believe,” “project,” “estimate,” “expect,” “strategy,”
“future,” “likely,” “may,” “should,” “will” and similar references
to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. In particular, our
expectations could be affected by uncertainties regarding the
success of our separation and spin-off from Novartis. Should one or
more of these uncertainties or risks materialize, or should
underlying assumptions prove incorrect, actual results may vary
materially from those anticipated. Therefore, you should not rely
on any of these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning more than seven decades, we offer the
broadest portfolio of products to enhance sight and improve
people’s lives. Our Surgical and Vision Care products touch the
lives of more than 260 million people in over 140 countries each
year living with conditions like cataracts, glaucoma, retinal
diseases and refractive errors. Our more than 20,000 associates are
enhancing the quality of life through innovative products,
partnerships with eye care professionals and programs that advance
access to quality eye care. Learn more at www.alcon.com.
References
- AcrySof®IQ PanOptix® Directions For Use.
- Compared to AcrySof® monofocal IOL.
Connect with us on Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191021005367/en/
Alcon Media Relations
Kimberly Wise +1 (817) 615 5092 (direct) +1 (817) 525 3409 (mobile)
kimberly.wise@alcon.com Alcon Investor
Relations Christina Cheng +41 589 112 110 (Geneva) +1
817 615 2789 (Fort Worth) investor.relations@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Jul 2023 to Jul 2024